The Role of Non-genetic Therapies to Reduce the Incidence of Sickle Cell Crisis: A Systematic Review.
- 2023-08-01
- Review
- Cureus 15(8)
- Shravya Pingili
- Vijaya Krishna Makkena
- Arturo P Jaramillo
- Babatope L Awosusi
- Javaria Ayyub
- Karan Nareshbhai Dabhi
- Namra V Gohil
- Nida Tanveer
- Sally Hussein
- Pousette Hamid
- PubMed: 37664256
- DOI: 10.7759/cureus.42785
- Low evidence
- Clinical
Voxelotor, crizanlizumab, L-glutamate, long-term blood transfusions, Zinc (Zn), Niprisan®, and Ciklavit* were found to reduce the number and severity of VOC.
- Effect
- Beneficial
- Effect size
- Small
- Significant
- Yes